Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

HANOVER INSURANCE GROUP, INC.
Next earnings Jul 28, 2026 · consensus $3.93 EPS, $1.67B rev
Last earnings -1.8% on 2026-04-29
P&C insurer with improved underwriting driving 18.5% ROE and a record $18.16 EPS, yet trades at just 10.9x.
Sources: SEC EDGAR (CIK 0000944695, latest 10-Q filed 2026-04-30) · EODHD · analysis by claude-code · as of 6/21/2026, 8:55:23 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
Quality fundamentals and an attractive price line up (~249% below fair value) — the rarer case where both the business and the entry look good.
The Hanover Insurance Group is a well-run property & casualty insurer (commercial, specialty, and personal lines) that has executed a clear underwriting turnaround. FY2025 net income jumped 55.5% to $663M and diluted EPS rose 55.2% to $18.16 on a 5.7% revenue increase to $6.59B, lifting ROE to a strong 18.5%. The trajectory is striking against recent history: net income was just $116M (FY2022) and $35.3M (FY2023) when elevated catastrophe and personal-lines losses crushed results, then recovered to $426M (FY2024) and now $663M. That rebound reflects rate increases earning through, tighter underwriting, and a more benign loss environment.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $5.23B | $5.47B | $5.99B | $6.24B | $6.59B |
| Gross profit | — | — | — | — | — |
| Operating income | $432M | $285M | $106M | $650M | $933M |
| Net income | $423M | $116M | $35.3M | $426M | $663M |
| Diluted EPS | $11.60 | $3.21 | $0.98 | $11.70 | $18.16 |
| Net margin | 8.1% | 2.1% | 0.6% | 6.8% | 10.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1482 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 0 open-market buys · 11 sales
| 2026-06-03 | Salvatore Bryan J Executive Vice President | Exercise | 16.4K @ $104.11 | $1.71M |
| 2026-06-03 | Salvatore Bryan J Executive Vice President | Sell | 16.4K @ $185.76 | $3.05M |
| 2026-05-21 | Aristeguieta Francisco Director | Sell | 1.00K @ $195.37 | $195K |
| 2026-05-20 | Roche John C President and CEO | Sell | 3.15K @ $193.21 | $609K |
| 2026-05-20 | Roche John C President and CEO | Sell | 5.14K @ $194.05 | $998K |
| 2026-05-20 | Roche John C President and CEO | Sell | 61.00 @ $194.77 | $11.9K |
| 2026-05-20 | Kerrigan Dennis Francis Executive Vice President | Exercise | 6.26K @ $115.35 | $722K |
| 2026-05-20 | Kerrigan Dennis Francis Executive Vice President | Sell | 6.26K @ $192.99 | $1.21M |
| 2026-05-19 | Roche John C President and CEO | Exercise | 9.10K @ $85.87 | $781K |
| 2026-05-19 | Roche John C President and CEO | Exercise | 24.0K @ $104.11 | $2.50M |
| 2026-05-19 | Roche John C President and CEO | Tax | 24.8K @ $193.79 | $4.80M |
| 2026-05-18 | Roche John C President and CEO | Sell | 375.00 @ $196.55 | $73.7K |